Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

1,980

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

September 14, 2021

Study Completion Date

September 14, 2021

Conditions
Influenza
Interventions
BIOLOGICAL

0.5ml Quadrivalent influenza vaccine

The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains

BIOLOGICAL

0.25ml Quadrivalent influenza vaccine

The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains

BIOLOGICAL

0.25ml Trivalent influenza vaccine(B/V)

The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains

BIOLOGICAL

0.25ml Trivalent influenza vaccine(B/Y)

The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains

Trial Locations (1)

450016

Henan Provincial Center for Disease Control and Prevention, Shangqiu

All Listed Sponsors
lead

Shanghai Institute Of Biological Products

INDUSTRY

NCT04363359 - Clinical Trial of Quadrivalent Influenza Virus Split Vaccine | Biotech Hunter | Biotech Hunter